Details of the Drug

General Information of Drug (ID: DMMSA9Y)

Drug Name
DNL593
Synonyms TAK-594
Indication
Disease Entry ICD 11 Status REF
Frontotemporal dementia 6D83 Phase 1/2 [1]
Drug Type
Fusion protein
Cross-matching ID
TTD ID
D2AG4O

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Progranulin (PGRN) TT4LM0E GRN_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05262023) A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Denali